Retention Rate of Acalabrutinib in a Non-interventional Setting

Inclusion Criteria:

• Age ≥ 18 years

• Diagnosis of CLL

• Ability to understand the study concept and to regularly complete patientquestionnaires from physical, mental, and linguistic perspectives

• Decision to start therapy with acalabrutinib according to the current SmPC. Forpreviously untreated patients as continuous therapy with or without obinutuzumab. ORFor patients with at least one prior CLL therapy as continuous monotherapy.

• Provision of signed informed consent form

Exclusion Criteria:

• Current or planned participation in an interventional clinical trial

• Contraindications to treatment with acalabrutinib according to the current SmPC

• Pregnancy or breast feeding

• Disease progression on prior BTKi therapy

• Start of acalabrutinib therapy more than 28 days prior to enrolment